文献速递临床试验与 GCP基础与转化研究

自体间充质干细胞治疗多发性硬化(MESEMS):一项随机双盲交叉I/II期临床试验

MEsenchymal StEm cells for Multiple Sclerosis (MESEMS): a randomized, double blind, cross-over phase I/II clinical trial with autologous mesenchymal stem cells for the therapy of multiple sclerosis.
PubMed 文献 · Trials · 2019-05-09

MESEMS是一项学术性、研究者发起的随机双盲安慰剂对照I/II期交叉试验,评估自体骨髓来源间充质干细胞(MSC)治疗多发性硬化的安全性和探索性疗效。受试者在基线或第24周接受自体MSC,主要共同目标是比较MSC与安慰剂治疗6个月时的安全性和疗效。研究通过整合部分独立临床试验、遵循统一方案并共享关键集中流程来克服资金限制。

要点

  • MESEMS为随机双盲交叉I/II期试验,比较自体骨髓MSC与安慰剂在6个月时的安全性和疗效。
  • 受试者在基线或第24周接受自体MSC,交叉设计评估MSC治疗。
  • 研究通过整合部分独立临床试验、共享集中数据收集与分析来克服资金限制。

核心结论

  • 研究结果将为患者和科学界提供MSC治疗多发性硬化的安全性和疗效数据。

研究设计与样本

  • 学术性、研究者发起的随机双盲安慰剂对照I/II期临床试验,采用自体骨髓来源MSC。
  • 受试者在基线或第24周接受自体MSC,采用交叉设计。
  • 主要共同目标为比较MSC与安慰剂治疗6个月时的安全性和疗效。
  • 次要目标为评估MSC在临床和MRI层面的疗效。
  • 研究整合部分独立临床试验,遵循统一方案并共享关键集中流程(包括数据收集和分析)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Multiple sclerosis (MS) is an inflammatory disease of the central nervous system with a degenerative component, leading to irreversible disability. Mesenchymal stem cells (MSC) have been shown to prevent inflammation and neurodegeneration in animal models of MS, but no large phase II clinical trials have yet assessed the exploratory efficacy of MSC for MS. METHODS/DESIGN: This is an academic, investigator-initiated, randomized, double-blind, placebo-compared phase I/II clinical trial with autologous, bone-marrow derived MSC in MS. Enrolled subjects will receive autologous MSC at either baseline or at week 24, through a cross-over design. Primary co-objectives are to test safety and efficacy of MSC treatment compared to placebo at 6 months. Secondary objectives will evaluate the efficacy of MSC at clinical and MRI levels. In order to overcome funding constraints, the MEsenchymal StEm cells for Multiple Sclerosis (MESEMS) study has been designed to merge partially independent clinical trials, following harmonized protocols and sharing some key centralized procedures, including data collection and analyses. DISCUSSION: Results will provide patients and the scientific community with data on the safety and efficacy of MSC for MS. The innovative approach utilized to obtain funds to support the MESEMS trial could represent a new model to circumvent limitation of funds encountered by academic trials. TRIAL REGISTRATION: Andalusia: NCT01745783 , registered on Dec 10, 2012. Badalona: NCT02035514 EudraCT, 2010-024081-21. Registered on 2012. Canada: ClinicalTrials.gov, NCT02239393 . Registered on September 12, 2014. Copenhagen: EudraCT, 2012-000518-13 . Registered on June 21, 2012. Italy: EudraCT, 2011-001295-19, and ClinicalTrials.gov, NCT01854957 . Retrospectively registered on May 16, 2013. London: Eudra CT 2012-002357-35, and ClinicalTrials.gov, NCT01606215 . Registered on May 25, 2012. Salzburg: EudraCT, 2015-000137-78 . Registered on September 15, 2015. Stockholm: ClinicalTrials.gov, NCT01730547 . Registered on November 21, 2012. Toulouse: ClinicalTrials.gov, NCT02403947 . Registered on March 31, 2015.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Uccelli A, Laroni A, Brundin L, et al. MEsenchymal StEm cells for Multiple Sclerosis (MESEMS): a randomized, double blind, cross-over phase I/II clinical trial with autologous mesenchymal stem cells for the therapy of multiple sclerosis. Trials. 2019. PMID: 31072380. doi:10.1186/s13063-019-3346-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。